Latest news with #Trastuzumab
Time of India
15-07-2025
- Health
- Time of India
Govt revises prices of 71 medicines, including those for diabetes and infections: Check new rates
The Centre has revised the prices of 71 important drug formulations, including those used to treat metastatic breast cancer, diabetes, peptic ulcers, and severe infections. The National Pharmaceutical Pricing Authority ( NPPA ) announced the new prices through a notification. As per the notification, manufacturers may add Goods and Services Tax (GST) only if they have paid or are liable to pay it on the retail price. Medicines for cancer, ulcers, and infections included Among the key drugs listed is Trastuzumab, produced by Reliance Life Sciences, used in the treatment of metastatic breast cancer and gastric cancer. Its price has been fixed at ₹11,966 per vial. Another drug, a combination of clarithromycin, esomeprazole, and amoxicillin used to treat peptic ulcer disease and manufactured by Torrent Pharmaceuticals , will now cost ₹162.5 per tablet. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Trekking pants for mountain sports and adventure travel Trek Kit India Shop Now Undo A combipack containing ceftriaxone, disodium edetate, and sulbactam powder for treating life-threatening infections has been priced at ₹626 per vial. A similar combination drug from Tyykem, in powder form for infusion, will now cost ₹515.5 per vial. Antidiabetic formulations also covered The NPPA notification also includes revised prices for 25 anti-diabetes formulations that contain sitagliptin. It also mentions several antidiabetic combinations containing empagliflozin. Live Events NPPA is the authority that monitors and sets the maximum retail prices of medicines in India to ensure accessibility and affordability. Retailers must display the revised price list In February, the NPPA had issued an order asking drug manufacturers to share the updated price lists with dealers, state drug controllers, and the government. This was aimed at ensuring transparency in drug pricing. "The order to display the price list is to allow citizens to cross-check whether the pharmacies are selling at the price fixed by NPPA or not," said an official. The NPPA's order also stated, "Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carried on business in a manner so as to be easily accessible to any person wishing to consult the same." The directive also applies to online retail platforms. (Inputs from TOI)
Time of India
15-07-2025
- Health
- Time of India
Centre fixes prices of 71 key drug formulations, including cancer medicines
Representative image NEW DELHI: The Centre has fixed the price of 71 key drug formulations, including medicines approved for treating metastatic breast cancer, allergies and diabetes, among others. Also, the notification issued by the National Pharmaceutical Pricing Authority (NPPA) states that the manufacturer may add Goods and Services Tax (GST) only if they have paid or it is payable to the government on the retail price. The drugs for which prices have been fixed include Trastuzumab by Reliance Life Sciences. It is used in the treatment of metastatic breast cancer and gastric cancer. The NPPA has fixed its price at Rs 11,966 per vial. The price of a combination drug containing clarithromycin, esomeprazole and amoxicillin which is used to treat peptic ulcer disease - a sore on the lining of the stomach - manufactured by Torrent Pharmaceuticals has been fixed at Rs 162.5 per tablet. The price of a combipack of ceftriaxone, disodium edetate and sulbactam powder used to treat life-threatening infections has been fixed at Rs 626 per vial. Another key drug combination used for treating infections containing ceftriaxone, disodium edetate and sulbactam powder for solution for Infusion from Tyykem has been priced at Rs 515.5 per vial, according to the NPPA notification. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Đây có thể là thời điểm tốt nhất để giao dịch vàng trong 5 năm qua IC Markets Tìm hiểu thêm Undo The NPPA has also notified the retail price of 25 anti-diabetes formulations containing sitagliptin as a component, apart from several other antidiabetic formulations containing empagliflozin as a combination in its latest notification. NPPA, a government regulatory agency, is responsible for controlling and revising the prices of pharmaceutical products in India. In February, the regulatory body issued an order stating that drug manufacturers must issue a price list to the dealers, state drug controllers and the government, indicating reference to such price fixation or revision as covered by the order or gazette notification issued by the government from time to time. "The order to display the price list is to allow citizens to cross-check whether the pharmacies are selling at the price fixed by NPPA or not," said an official. "Every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carried on business in a manner so as to be easily accessible to any person wishing to consult the same," the NPPA's February order stated. It added that the directive also covers the virtual/online premises where the retailer or dealer carries on business.
Business Wire
24-06-2025
- Business
- Business Wire
Trially AI Taps Serial Entrepreneur Christian Smith as CRO to Expand AI Clinical Trial Enrollment Across U.S.
KANSAS CITY, Mo.--(BUSINESS WIRE)-- Trially®, a breakthrough AI clinical trial recruitment technology to unlock faster qualified patient enrollment, today announced the appointment of as Chief Revenue Officer. A serial entrepreneur and proven operator, Smith brings a track record of scaling quality service for healthcare organizations and will lead efforts to accelerate trial enrollment for U.S. site networks, healthcare systems, and sponsors with Trially's AI tools. When my mom passed away of breast cancer in 2005, we had no clue there were 28 studies running within driving distance, including studies for Trastuzumab and Bevacizumab which represent some of the top treatments on the market today. Smith joins Trially at a pivotal moment. As clinical research sites face mounting enrollment pressure and shrinking pipelines, Trially has emerged as a category-defining technology. In a landscape where 68% of sites miss enrollment targets and screen failure rates continue to rise, Trially AI is enabling sites to predictably prescreen and qualify patients for trials — with or without an EHR integration — helping teams multiply enrollment for even the most complex protocols in record time. 'In my late teens, I found how difficult it is to navigate medical care when standard treatment paths do not yield results,' said Smith. 'When my mom passed away of breast cancer in 2005, we had no clue there were 28 studies running within driving distance, including studies for Trastuzumab and Bevacizumab which represent some of the top treatments on the market today. It is an honor to join Trially to serve the physician networks and sites by matching patients with novel drug therapies to improve health outcomes and the standard of care.' Prior to Trially, Smith co-founded TrackR, where he helped create the Bluetooth tracking category and grew revenue to over $50 million. During the COVID-19 pandemic, he led direct-to-consumer operations at Dascena, opening 44 testing sites across 26 cities. Most recently, he co-founded Forta, where he pioneered a family centric autism therapy model powered by AI. His expertise in direct-to-patient recruitment, AI-driven care models, and scaling operational quality — are critical to best support Trially partners. 'Christian brings the exact mindset we value at Trially: efficiency, transparency, empathy,' said Trevor Welch, Co-founder and Chief Product Officer of Trially. "He understands what it means to scale with purpose, and he's passionate about empowering research teams to help patients get access to life-saving therapies. His arrival marks a new chapter in our mission to unlock faster qualified patient enrollment across the industry.' About Trially Trially® is shaping the future of clinical trial recruitment with its proprietary AI matching technology that safely unlocks rich clinical data to enroll qualified patients faster. Proven to multiply enrollment rates by 200%, dramatically reduce screen failures and improve site efficiency, Trially's site-based software rapidly integrates with any EHR or CTMS system while maintaining full compliance with HIPAA, SOC 2, FDA 21 CFR Part 11 and ISO 27001 regulations. Designed to meet the needs of physicians, research sites and pharmaceutical sponsors, Trially empowers you to achieve outstanding results in clinical research. For more information visit
Business Standard
24-06-2025
- Health
- Business Standard
Biocon Biologics partners with National Cancer Society of Malaysia
To launch a Patient Assistance Program (PAP) in Malaysia Biocon Biologics has partnered with the National Cancer Society of Malaysia (NCSM), a prominent not-for-profit cancer organization, to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. Biocon Biologics will provide quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will start with providing bTrastuzumab to cancer patients facing treatment delays due to budget constraints. The MoU was signed during the National Cancer Congress Malaysia 2025 event, emphasizing a commitment to improving patient-centric healthcare.
BusinessToday
24-06-2025
- Health
- BusinessToday
National Cancer Malaysia Partners Biocon In Offering Affordable Cancer Care For The Underserved
Biocon Biologics Limited, has partnered with the National Cancer Society of Malaysia to launch a Patient Assistance Program (PAP) in Malaysia aimed at improving access to affordable, high-quality biosimilars for underserved cancer patients in Malaysia. The partnership will see Biocon Biologics providing quality-assured biosimilars from its oncology portfolio, including Trastuzumab, Pegfilgrastim and Bevacizumab, to NCSM, which will manage patient enrolment and medicine supply as part of its healthcare services. This collaboration combines Biocon's expertise in biosimilars with NCSM's community outreach to enhance cancer care accessibility and affordability in Malaysia. The program will start with providing Trastuzumab to cancer patients facing treatment delays due to budget constraints. Ratish Trehan, Head of Commercial – Emerging Markets, Biocon Biologics, said, 'Together, we hope to positively impact thousands of lives and strengthen Malaysia's efforts to deliver inclusive, patient-centric healthcare.' Biocon Biologics aims to build on its previous success in expanding access to diabetes care in Malaysia, having served over 345,000 patients, and is now focusing on oncology through strategic partnerships like this. Related
